MDXG (MiMedx Group) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDXG MiMedx Group Inc MDXG
58 GF Score
Price $4.30
GF Value $7.54
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is MiMedx Group Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MDXG vs RGNX, ACHV, AGMB: Short Interest Comparison

For the Biotechnology subindustry, MiMedx Group's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiMedx Group Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiMedx Group's Short Interest distribution charts can be found below:

* The bar in red indicates where MiMedx Group's Short Interest falls into.


MDXG
58GF Score
MiMedx Group Inc MDXG
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MiMedx Group (MDXG) Overvalued in 2026?

Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued. The current stock price of $4.30 is trading 43% below its estimated GF Value™ of $7.54. GuruFocus considers MiMedx Group to be Significantly Undervalued.

Key valuation signals for MDXG:

  • Short Interest:
  • GF Value™: $7.54 vs. price of $4.30 (43% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MiMedx Group Business Description

Address 1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
58GF Score

Get the complete analysis for MDXG

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.30
Price
$7.54
GF Value